Positive statement

Teleperformance SE: Final Results of the Offer for Majorel

Retrieved on: 
Friday, November 3, 2023

This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Teleperformance or Majorel.

Key Points: 
  • This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Teleperformance or Majorel.
  • A total of 78,984,447 Shares have been tendered against the Share Consideration during the Offer Period and the Post-Acceptance Period.
  • Teleperformance intends to offer the amount of the Cash Consideration (i.e., EUR 30 per Share) as part of these squeeze-out proceedings.
  • Reference is made to Section 6.13 (Consequences of the Offer for non-tendering Shareholders) of the Offer Memorandum.

Teleperformance declares Offer for Majorel unconditional 98.45% of Shares tendered under the Offer – Opening of the Post-Acceptance Period

Retrieved on: 
Friday, October 20, 2023

As a result, Teleperformance declares the Offer unconditional (doet gestand) and the Post-Acceptance Period will start as from 23 October 2023 for a 2-week period.

Key Points: 
  • As a result, Teleperformance declares the Offer unconditional (doet gestand) and the Post-Acceptance Period will start as from 23 October 2023 for a 2-week period.
  • Shareholders who have elected to receive the Share Consideration during the Offer Period or the Post-Acceptance Period will receive on the Second Settlement Date Teleperformance shares at an exchange ratio of 30/217.
  • Further information on the Post-Acceptance Period is included in Section 5.8 (Post-Acceptance Period) of the Offer Memorandum.
  • A maximum of 4,608,295 Teleperformance shares is available for issue under the Share Consideration, (i.e., a maximum of 33,333,334 Shares can be exchanged for Teleperformance shares).

National Headache Foundation Position Statement on the Treatment of Migraine

Retrieved on: 
Wednesday, January 19, 2022

Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.

Key Points: 
  • Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.
  • Unfortunately, the current care models adopted by payers (health insurance) have not kept pace with the many advances in treatment.
  • The vision of the National Headache Foundation (NHF) is a world without headache.
  • In the future, NHF will expand upon this Position Statement and propose specific treatment guidelines.